Pacira BioSciences
PCRX
258 hedge funds and large institutions have $1.88B invested in Pacira BioSciences in 2023 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 95 increasing their positions, 94 reducing their positions, and 41 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
17% more call options, than puts
Call options by funds: $8.6M | Put options by funds: $7.33M
1.3% more ownership
Funds ownership: 100.87% → 102.18% (+1.3%)
1% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 94
1% less capital invested
Capital invested by funds: $1.89B → $1.88B (-$10.1M)
3% less funds holding
Funds holding: 267 → 258 (-9)
15% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
+$32.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.4M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$19.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$15.8M |
| 5 |
Janus Henderson Group
London,
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$65.3M |
| 2 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$33.9M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$21M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.8M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$9.6M |
PCRX Hedge Fund Activity: Q2 2023 in Review
258 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2023, worth a combined $1.88B — down 0.53% from $1.89B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of PCRX and 35 opened new positions — a net loss of 6 holders — while 94 trimmed existing stakes and 95 added.
The largest buyer was Prosight Management, adding an estimated $32.5M. The largest seller was Millennium Management, cutting an estimated $65.3M.
- 258 institutional investors held Pacira BioSciences (PCRX) as of Q2 2023, down from 267 in Q1 2023.
- Funds reported $1.88B of Pacira BioSciences stock for Q2 2023, down 0.53% quarter-over-quarter.
- 35 funds opened new Pacira BioSciences positions in Q2 2023 and 41 closed out, a net change of -6 holders.
- The largest Pacira BioSciences buyer in Q2 2023 was Prosight Management, an estimated $32.5M added.
- The largest Pacira BioSciences seller in Q2 2023 was Millennium Management, an estimated $65.3M sold.
Based on aggregated 13F filings for Q2 2023.